| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Executive Chairman
4 companies
Johnson John serves as a Director at XERS and has filed Form 4s across 4 companies. Across recent SEC filings that breaks down to 0 buys and 9 sells.
Historically, Johnson John's trades have earned a below-average insider score of 23/100 across 5 rated trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -100.0%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 4, 2026 | XERS Xeris Biopharma Holdings, Inc. | Director | Sell10b5-1 | 15,000 | $6.09 | $91,422.00 | -2.1% | +39.5% | - | |
| May 7, 2026 | AXGN Axogen, Inc. | Director | Sale+OE | 11,050 | $43.26 | $477,967.75 | - | +4.2% | - | |
| Dec 19, 2025 | XERS Xeris Biopharma Holdings, Inc. | Director | Sell | 135,400 | $7.22 | $977,019.32 | -16.2% | -24.0% | - | |
| Dec 9, 2025 | AXGN Axogen, Inc. | Director | Sale+OE | 45,379 | $30.64 | $1,390,392.87 | - | -4.3% | - | |
| Aug 13, 2025 | XERS Xeris Biopharma Holdings, Inc. | Director | Sell | 107,500 | $7.32 | $786,459.25 | -11.4% | +2.2% | +14.4% | |
| Jun 9, 2025 | AXGN Axogen, Inc. | Director | Sell | 4,073 | $10.61 | $43,214.53 | -14.0% | +54.1% | +311.8% |